These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
378 related articles for article (PubMed ID: 35805978)
1. Pathophysiology and Emerging Molecular Therapeutic Targets in Heterotopic Ossification. Felix-Ilemhenbhio F; Pickering GAE; Kiss-Toth E; Wilkinson JM Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35805978 [TBL] [Abstract][Full Text] [Related]
2. BMP and mTOR signaling in heterotopic ossification: Does their crosstalk provide therapeutic opportunities? Wu J; Ren B; Shi F; Hua P; Lin H J Cell Biochem; 2019 Aug; 120(8):12108-12122. PubMed ID: 30989716 [TBL] [Abstract][Full Text] [Related]
3. Targeted stimulation of retinoic acid receptor-γ mitigates the formation of heterotopic ossification in an established blast-related traumatic injury model. Pavey GJ; Qureshi AT; Tomasino AM; Honnold CL; Bishop DK; Agarwal S; Loder S; Levi B; Pacifici M; Iwamoto M; Potter BK; Davis TA; Forsberg JA Bone; 2016 Sep; 90():159-67. PubMed ID: 27368930 [TBL] [Abstract][Full Text] [Related]
5. Surgical Excision of Heterotopic Ossification Leads to Re-Emergence of Mesenchymal Stem Cell Populations Responsible for Recurrence. Agarwal S; Loder S; Cholok D; Li J; Breuler C; Drake J; Brownley C; Peterson J; Li S; Levi B Stem Cells Transl Med; 2017 Mar; 6(3):799-806. PubMed ID: 28297577 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of Hif1α prevents both trauma-induced and genetic heterotopic ossification. Agarwal S; Loder S; Brownley C; Cholok D; Mangiavini L; Li J; Breuler C; Sung HH; Li S; Ranganathan K; Peterson J; Tompkins R; Herndon D; Xiao W; Jumlongras D; Olsen BR; Davis TA; Mishina Y; Schipani E; Levi B Proc Natl Acad Sci U S A; 2016 Jan; 113(3):E338-47. PubMed ID: 26721400 [TBL] [Abstract][Full Text] [Related]
7. Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor-γ agonists. Shimono K; Tung WE; Macolino C; Chi AH; Didizian JH; Mundy C; Chandraratna RA; Mishina Y; Enomoto-Iwamoto M; Pacifici M; Iwamoto M Nat Med; 2011 Apr; 17(4):454-60. PubMed ID: 21460849 [TBL] [Abstract][Full Text] [Related]
8. The role of Activin A in fibrodysplasia ossificans progressiva: a prominent mediator. Lin H; Shi F; Gao J; Hua P Biosci Rep; 2019 Aug; 39(8):. PubMed ID: 31341010 [TBL] [Abstract][Full Text] [Related]
9. Palovarotene inhibits the NF-κB signalling pathway to prevent heterotopic ossification. Huang J; Wu J; Lin J; Li C; Tang B; Xiao H Clin Exp Pharmacol Physiol; 2022 Aug; 49(8):881-892. PubMed ID: 35638441 [TBL] [Abstract][Full Text] [Related]
10. Depletion of Mast Cells and Macrophages Impairs Heterotopic Ossification in an Acvr1 Convente MR; Chakkalakal SA; Yang E; Caron RJ; Zhang D; Kambayashi T; Kaplan FS; Shore EM J Bone Miner Res; 2018 Feb; 33(2):269-282. PubMed ID: 28986986 [TBL] [Abstract][Full Text] [Related]
11. Conserved signaling pathways underlying heterotopic ossification. Kan C; Chen L; Hu Y; Ding N; Lu H; Li Y; Kessler JA; Kan L Bone; 2018 Apr; 109():43-48. PubMed ID: 28455214 [TBL] [Abstract][Full Text] [Related]
12. Challenges of heterotopic ossification-Molecular background and current treatment strategies. Łęgosz P; Drela K; Pulik Ł; Sarzyńska S; Małdyk P Clin Exp Pharmacol Physiol; 2018 Dec; 45(12):1229-1235. PubMed ID: 30144316 [TBL] [Abstract][Full Text] [Related]
13. Palovarotene Inhibits Heterotopic Ossification and Maintains Limb Mobility and Growth in Mice With the Human ACVR1(R206H) Fibrodysplasia Ossificans Progressiva (FOP) Mutation. Chakkalakal SA; Uchibe K; Convente MR; Zhang D; Economides AN; Kaplan FS; Pacifici M; Iwamoto M; Shore EM J Bone Miner Res; 2016 Sep; 31(9):1666-75. PubMed ID: 26896819 [TBL] [Abstract][Full Text] [Related]
14. Metformin attenuates trauma-induced heterotopic ossification via inhibition of Bone Morphogenetic Protein signalling. Lin H; Shi F; Jiang S; Wang Y; Zou J; Ying Y; Huang D; Luo L; Yan X; Luo Z J Cell Mol Med; 2020 Dec; 24(24):14491-14501. PubMed ID: 33169942 [TBL] [Abstract][Full Text] [Related]